AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?

Company Performance - AxoGen (AXGN) shares have increased by 27.5% over the past month, reaching a new 52-week high of $18.4 [1] - Year-to-date, AxoGen has gained 9.5%, outperforming the Zacks Medical sector, which declined by 4.5%, and the Zacks Medical - Instruments industry, which returned 6.5% [1] Earnings and Revenue - AxoGen has consistently exceeded earnings expectations, reporting EPS of$ 0.07 in its last earnings report, surpassing the consensus estimate of $0 [2] - For the current fiscal year, AxoGen is projected to earn$ 0.31 per share on revenues of $185.2 million, with a year-over-year earnings growth of 251.85% [3] - For the next fiscal year, earnings are expected to rise to$ 0.48 per share on revenues of $208.47 million, reflecting a year-over-year change of 12.56% [3] Valuation Metrics - AxoGen has a Value Score of D, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of B [6] - The stock trades at 57.6X current fiscal year EPS estimates, which is above the peer industry average of 27.6X [6] - On a trailing cash flow basis, AxoGen trades at 5X compared to the peer group's average of 16.8X [6] Zacks Rank - AxoGen holds a Zacks Rank of 2 (Buy), indicating rising earnings estimates and meeting the criteria for potential investment [7] Industry Comparison - The Medical - Instruments industry is positioned in the top 35% of all industries, suggesting favorable conditions for both AxoGen and its peer, Penumbra, Inc. (PEN) [10] - Penumbra, Inc. has a Zacks Rank of 1 (Strong Buy) and is expected to post earnings of$ 3.86 per share on revenue of $1.19 billion for the current fiscal year [9]